R
Richard M. Weinshilboum
Researcher at Mayo Clinic
Publications - 571
Citations - 33641
Richard M. Weinshilboum is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacogenetics & Thiopurine methyltransferase. The author has an hindex of 86, co-authored 529 publications receiving 31166 citations. Previous affiliations of Richard M. Weinshilboum include University of Rochester & Royal Hallamshire Hospital.
Papers
More filters
Journal ArticleDOI
Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.
Herbert M. Lachman,Demitri F. Papolos,Takuya Saito,Yue Min Yu,Carol L. Szumlanski,Richard M. Weinshilboum +5 more
TL;DR: The identification of a gentic marker associated with significant alterations in enzyme activity will facilitate the analysis of a possible role for the COMT gene in neuropsychiatric conditions in which abnormalities in catecholamine neurotransmission are believed to occur.
Journal Article
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.
TL;DR: The segregation of RBC TPMT activity among 215 first-degree relatives in 50 randomly selected families and among 35 members of two kindreds and one family selected because they included probands with undetectable RBC enzyme activity were also compatible with the autosomal codominant inheritance of RBNT.
Journal ArticleDOI
Inheritance and Drug Response
TL;DR: The underlying message is that inherited variations in drug effect are common and that some tests that incorporate pharmacogenetics into clinical practice are now available, with many more to follow.
Journal ArticleDOI
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
Y. Jin,Zeruesenay Desta,Vered Stearns,Bryan A. Ward,Herbert Ho,K. Lee,Todd C. Skaar,Anna Maria Storniolo,Lang Li,Adjei Araba,Rebecca L. Blanchard,Anne Nguyen,Lynda Ullmer,Jill Hayden,Suzanne Lemler,Richard M. Weinshilboum,James M. Rae,Daniel F. Hayes,David A. Flockhart +18 more
TL;DR: Interactions between CYP2D6 polymorphisms and coadministered antidepressants and other drugs that are CYP 2D6 inhibitors may be associated with altered tamoxifen activity.
Journal ArticleDOI
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
TL;DR: Results indicate that genetically determined TPMT activity may be a substantial regulator of the cytotoxic effect of 6-MP, an effect which in turn could be important in influencing the outcome of therapy for childhood ALL.